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LUNG CANCER
Integrated FDG-PET/CT does not make invasive staging of the
intrathoracic lymph nodes in non-small cell lung cancer
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Background: Staging of non-small cell lung cancer (NSCLC) is important for determining choice of treatment
and prognosis. The accuracy of FDG-PET scans for staging of lymph nodes is too low to replace invasive
nodal staging. It is unknown whether the accuracy of integrated FDG-PET/CT scanning makes invasive
staging redundant.
Methods: In a prospective study, the mediastinal and/or hilar lymph nodes in patients with proven NSCLC
were investigated with integrated FDG-PET/CT scanning. Pathological confirmation of all suspect lymph
nodes was obtained to calculate the accuracy of the fusion images. In addition, the use of the standardised
uptake value (SUV) in the staging of intrathoracic lymph nodes was analysed.
Results: 105 intrathoracic lymph node stations from 52 patients with NSCLC were characterised. The
prevalence of malignancy in the lymph nodes was 36%. The sensitivity of the integrated FDG-PET/CT scan to
detect malignant lymph nodes was 84% and its specificity was 85% (positive likelihood ratio 5.64, negative
likelihood ratio 0.19). SUVmax, SUVmean and the SUVmax/SUVliver ratio were all significantly higher in
malignant than in benign lymph nodes. The area under the receiver operating curve did not differ between
these three quantitative variables, but the highest accuracy was found with the SUVmax/SUVliver ratio. At a
cut-off value of 1.5 for the SUVmax/SUVliver ratio, the sensitivity and specificity to detect malignant lymph
node invasion were 82% and 93%, respectively.
Conclusion: The accuracy of integrated FDG-PET/CT scanning is too low to replace invasive intrathoracic
lymph node staging in patients with NSCLC. The visual interpretation of the fusion images of the integrated
FDG-PET/CT scan can be replaced by the quantitative variable SUVmax/SUVliver without loss of accuracy for
intrathoracic lymph node staging.
S
taging non-small lung cancer (NSCLC) is an important
part of the diagnostic course in patients with lung cancer
since it guides the treatment modalities and predicts
survival.1 While staging with computed tomography (CT) has
an important role in the initial staging by providing excellent
anatomical information on the extent of the primary tumour (T
denominator), the CT scan has limited ability to differentiate
between benign and malignant lymph nodes (N denominator).
Whole body positron emission tomography (PET) with 18-
fluoro-2-deoxy-D-glucose (FDG) has a higher accuracy for
detecting intrathoracic lymph node metastasis,2–4 and demon-
strates occult distant metastasis in approximately 10% of
patients.2 According to other reports, CT and FDG-PET perform
similarly in mediastinal staging.5 Because of an unacceptable
rate of false positive and false negative findings, FDG-PET has
been shown to be insufficiently accurate to replace invasive
lymph node staging on tissue specimens.6–8 In addition, the
visual localisation of intrathoracic lymph nodes with FDG-PET
is not always unequivocal because of the low spatial resolution
of the PET images.
Integrated FDG-PET/CT scans theoretically overcome this
problem because of the co-acquisition of CT and FDG-PET
images resulting in so-called fusion images. Lardinois et al9
showed that, in 50 patients with NSCLC, the integrated FDG-
PET/CT scan was more accurate than FDG-PET alone for nodal
staging; however, no difference in accuracy was noted when
integrated FDG-PET/CT scans were compared with CT scans
alone. Several investigators have indicated that the maximum
standardised uptake value (SUVmax) of the primary tumour is a
prognostic factor in patients with NSCLC.10 11 With the
integrated FDG-PET/CT scan, the application of this quantita-
tive technique at the level of the lymph node becomes more
precise since the anatomical borders of the lymph nodes can be
exactly identified for determining the region of FDG uptake.12
From a clinical point of view, an accuracy or a negative/
positive predictive value of at least 90–95% for the integrated
FDG-PET/CT scan is required to make invasive staging
redundant. To evaluate whether tissue-confirmed lymph node
staging by surgery or echo-endoscopy can be avoided, we
prospectively assessed the accuracy of the integrated FDG-PET/
CT scan in the nodal staging of NSCLC. In addition, we
investigated whether an objective measure of FDG uptake
based on SUV values could substitute for the subjective
interpretation of the fusion images.
METHODS
Patients
Consecutive patients with suspected or pathologically proven
primary NSCLC were eligible if a tissue specimen from at least
one of the intrathoracic lymph nodes was available and if they
underwent an integrated FDG-PET/CT scan. All investigations
were done before the start of any treatment, and both the
integrated PET/CT scan and examination of lymph node tissue
Abbreviations: CT, computed tomography; EBUS-TBNA, endobronchial
endoscopic ultrasound with real-time guided transbronchial needle
aspiration; EUS-FNA, endoscopic ultrasound with real-time guided fine
needle aspiration; FDG, 18-fluoro-2-deoxy-D-glucose; NSCLC, non-small
cell lung cancer; PET, positron emission tomography; ROC, receiver
operating curve; SUV, standardised uptake value
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were performed within 14 days of each other. The study was
approved by the ethics committee of Ghent University Hospital.
Pathology of primary lung tumours and of intrathoracic
lymph nodes
A tissue specimen of the primary tumour was obtained for
pathological examination by either bronchoscopy, CT-guided
transthoracic puncture or a surgical procedure (thoracotomy or
video-assisted thoracoscopy). For intrathoracic lymph nodes, a
tissue sample was obtained either by mediastinoscopy, surgical
resection or by linear endoscopic ultrasound. The latter
consisted of either oesophageal endoscopic ultrasound with
real-time guided fine needle aspiration (EUS-FNA) or endo-
bronchial endoscopic ultrasound with real-time guided trans-
bronchial needle aspiration (EBUS-TBNA). Because the
negative predictive values of EUS-FNA and EBUS-TBNA are
considered too low,13 14 surgical confirmation was always done
in case no malignant lymph node invasion could be demon-
strated by either of these endoscopic techniques.
Staging procedures with CT and FDG-PET/CT
Patients fasted for at least 6 hours, after which blood glucose
levels were determined to ascertain a level of ,200 mg/dl.
Patients then received 4 MBq/kg FDG intravenously followed
by 250 ml sodium chloride and 20 mg furosemide. For muscle
relaxation and to minimise background staining, diazepam
5 mg was given orally. Image acquisition started 60 min after
injection of FDG in a relaxed supine position with the arms
alongside the body using an integrated FDG-PET/CT scanner
(Philips Gemini FDG-PET/CT, Philips Medical Systems,
Cleveland, Ohio, USA). First, a total body low-dose CT scan
for calculation of the attenuation correction was performed
(120 kV, effective tube current-time product maximum
30 mAS, pitch 0.9, collimation 1661.5 mm, rotation time
0.5 s, reconstructed contiguous slices of 5 mm, scan field from
head up to the upper tights). Second, a scan was performed
with a dual head injector (175 mAS, otherwise the same scan
parameters) after intravenous injection of 120 ml contrast
medium with an iodine concentration of 300 mg/ml at a flow
rate of 1.8 ml/s followed by a saline flush. No oral contrast was
administered. Next, the FDG-PET scan from the orbitomeatal
region up to the upper tights (consisting of 8–9 bed positions of
3 min per table position) was performed. Patients were
instructed to breathe normally during the acquisition of the
CT and FDG-PET/CT images. PET image data sets were
reconstructed iteratively using a row action maximum like-
lihood algorithm with segmented correction for attenuation
with use of the CT data. Co-registered images were displayed by
means of SYNTEGRA software (Philips Medical Systems).
The CT and integrated FDG-PET/CT scans represented a
single procedure of data acquisition but were read separately.
For the CT analysis the radiologist was blinded to the FDG-PET
data. All intrathoracic lymph nodes were noted and the small
and long axes were measured (mm). A lymph node with a short
axis of at least 10 mm was indicated as suspect. The FDG-PET/
CT scan was interpreted based on both CT and FDG-PET images
which were read by a nuclear physician and a radiologist.
Determination of FDG-PET/CT SUV variables
The maximum and mean SUV values were determined by
drawing regions of interest on the attenuation-corrected FDG-
PET fusion images around the primary tumour or the involved
lymph node. The variables SUVmax and SUVmean were then
calculated as the maximum and mean SUV values, respectively,
within the region of interest. Quantitative evaluation based on
the SUVmax/SUVliver ratio was calculated as the ratio of the
SUVmax over the mean SUV value obtained from the homo-
genous distribution of radioactivity in the liver.15
Statistical analysis
A clinical research form was completed for each patient and
integrated in an electronic database for analysis with SPSS 14.0
(SPSS Inc, Chicago, Illinois, USA). Except for the demographic
data, calculations were primarily performed at the single lymph
node level. The test characteristics of the CT scan and integrated
FDG-PET/CT scan were also calculated at the individual patient
level. Values are expressed as mean (SD). Continuous variables
were compared with the Mann-Whitney U test and Kruskal-
Wallis test. Comparison of proportions (accuracy analysis) was
done with a Z-test. A two-sided p value of ,0.05 was
considered statistically significant. The receiver operating
curves (ROC) and the ROC areas, the latter being a parameter
to measure how well a certain variable can distinguish between
benign and malignant lymph nodes, were analysed with SPSS
14.0 and compared with Medcalc Version 9.1.0.1.
RESULTS
Characteristics of patients and procedures
The study included 52 patients with NSCLC whose character-
istics are shown in table 1. Patients were recruited between
November 2005 and April 2006. A diagnosis of NSCLC was
obtained in the primary tumour specimen in 67% of cases. For
the others, the diagnosis was extrapolated from the malignant
cells found in the lymph node specimen. 52% of the patients
had at least one malignant intrathoracic lymph node.
Integrated FDG-PET/CT analysis and tissue specimens were
obtained for 105 intrathoracic lymph nodes from 50 patients
(an average of 2.01 lymph nodes per patient). In two patients
the integrated FDG-PET/CT scan was useful for evaluating the
primary tumour only as its central location precluded a
confident discrimination of mediastinal lymph nodes. In 10%
of the patients a confirmatory surgical staging technique was
Table 1 Characteristics of patients and
investigations
n
Number of patients 52




Median (range) age (years) 68 (48–80)






Primary tumour pathology obtained 35 (67%)
With bronchoscopy 17 (49%)
With transthoracic puncture (CT guided) 5 (14%)
With a surgical procedure 13 (37%)
Site of thoracic lymph nodes
Upper mediastinum (2–3–4–5–6) 50 (48%)
Subcarinal region (7) 32 (31%)
Lower mediastinum (8–9) 12 (11%)
Hilar lymph nodes (10–11) 11 (10%)
Lymph node pathology obtained 50 (96%)
With mediastinoscopy/surgery 21 (42%)
With EUS-FNA or EBUS-TBNA 24 (48%)
With EUS-FNA or EBUS-TBNA followed by
surgical staging
5 (10%)
LUL, left upper lower; LLL, left lower lobe; RUL, right upper lobe;
RLL, right lower lobe; RML, right middle lobe; EUS-FNA,
endoscopic ultrasound with real-time guided fine needle
aspiration; EBUS-TBNA, endobronchial endoscopic ultrasound
with real-time guided transbronchial needle aspiration.
Integrated FDG-PET/CT in lung cancer staging 697
www.thoraxjnl.com
 on 8 August 2007 thorax.bmj.comDownloaded from 
necessary because of a negative endoscopic ultrasound exam-
ination.
Standardised uptake values for the primary tumour
Table 2 shows the mean values of the different SUV variables
for the primary tumours. There was no difference in SUVmax,
SUVmean or in the ratio SUVmax/SUVliver between the different
histological subtypes of NSCLC (Kruskal-Wallis test), nor
between squamous and non-squamous carcinomas. Both
standard deviation (table 2) and variance (data not shown)
of the SUV variables indicate that the spread of the SUVmax was
considerably larger than for SUVmean or the SUVmax/SUVliver
ratio. In addition, lung tumours ,3 cm had a statistically
significant lower SUVmax, SUVmean and SUVmax/SUVliver than
tumours .3 cm. We did not find a significant correlation
between the four T stages and the respective SUV values (data
not shown).
Accuracy of CT and integrated FDG-PET/CT for staging
lymph nodes
The accuracy of the CT findings and of the integrated FDG-PET/
CT fusion images for staging intrathoracic lymph nodes is
shown in table 3. The prevalence of malignant lymph nodes
was 36%. Whereas the sensitivity of CT and integrated FDG-
PET/CT scans to detect malignant lymph node invasion was
equal (both 84%), integrated FDG-PET/CT scanning had a
specificity of 85% compared with 61% for the CT scan. The
accuracy for detecting malignant intrathoracic lymph nodes
was 69% and 85%, respectively, for CT scans and integrated
FDG-PET/CT scans. These figures do not differ significantly
from the accuracy of the CT scan (74%) and integrated FDG-
PET/CT scan (84%) calculated at the level of the individual
patient. The negative predictive value of small lymph nodes
(short axis ,10 mm) without uptake of FDG was 91% (95% CI
77% to 97%; n = 43); the positive predictive value of enlarged
lymph nodes (short axis .10 mm) with FDG uptake was 79%
(95% CI 62% to 90%; n = 38); the negative predictive value of
enlarged lymph nodes without uptake of FDG was 90% (95% CI
60% to 98%; n = 20); and the positive predictive value of small
lymph nodes with FDG uptake was 50% (95% CI 6% to 93%;
n = 4).
Standardised uptake values for intrathoracic lymph
nodes and ROC curves
Figure 1 shows the SUV-based quantitative integrated FDG-
PET/CT characteristics for intrathoracic lymph node staging. A
statistically significant difference was observed between benign
and malignant lymph nodes for SUVmax, SUVmean and for the
SUVmax/SUVliver ratio. This difference was found in the
enlarged lymph nodes but not in the smaller ones (data not
shown). The ROC curves, ROC area and cut-off values are
shown in fig 2. No statistical difference between these three
variables was found. For SUVmax the cut-off value for the
highest accuracy was 2.9, which corresponds to a sensitivity of
76% and a specificity of 90%. For SUVmean the highest accuracy
was reached at a cut-off point of 2.3, yielding a sensitivity of
Table 2 Mean (SD) PET/CT data for the primary tumour in patients with non-small cell lung
cancer (NSCLC)
N SUVmax SUVmean SUVmax/SUVliver
All NSCLC 52 8.34 (4.02) 4.74 (2.57) 4.78 (2.18)
Adenocarcinoma 17 (33%) 7.50 (3.79) 4.72 (3.12) 4.06 (2.22)
Squamous cell carcinoma 20 (38%) 9.04 (4.61) 4.91 (2.85) 5.37 (2.30)
Large cell carcinoma 10 (19%) 8.32 (3.41) 4.46 (1.20) 4.38 (1.33)
Adenosquamous carcinoma 5 (10%) 8.47 (4.08) 4.71 (1.82) 5.64 (2.51)
T1 tumours ( 3 cm) 16 (31%) 6.65 (3.42) 3.71 (1.87) 3.77 (1.52)
T2–4 tumours (.3 cm) 36 (69%) 9.10 (4.09) 5.20 (2.73) 5.23 (2.29)
Mann-Whitney U test p = 0.026 p = 0.036 p = 0.008
SUV, standardised uptake value.
Table 3 Accuracy of interpretation of computed tomography (CT) scans versus integrated
whole body positron emission tomography with 18-fluoro-2-deoxy-D-glucose/CT (FDG-PET/







n = 67 (64%)
Malignant lymph
nodes
n = 38 (36%)
CT read-out
CT positive (short axis range 10–40 mm) 58 (55%) 26 (39%) 32 (84%)
CT negative (short axis range 1–9 mm) 47 (45%) 41 (61%) 6 (16%)
CT sensitivity 84 (68–93)
CT specificity 61 (48–73)
CT LR+ 2.17 (1.56–3.02)
CT LR– 0.26 (0.12–0.55)
PET/CT read-out
PET/CT positive (fusion images) 42 (40%) 10 (15%) 32 (84%)
PET/CT negative (fusion images) 63 (60%) 57 (85%) 6 (16%)
PET/CT sensitivity 84 (68–93)
PET/CT specificity 85 (74–92)
PET/CT LR+ 5.64 (3.13–10.16)
PET/CT LR– 0.19 (0.09–0.39)
LR+, positive likelihood ratio; LR–, negative likelihood ratio.
Statistical analysis CT vs integrated PET/CT read-out: sensitivity, NS; specificity, p = 0.002; positive likelihood ratio,
p,0.001; negative likelihood ratio, NS.
698 Tournoy, Maddens, Gosselin, et al
www.thoraxjnl.com
 on 8 August 2007 thorax.bmj.comDownloaded from 
68% and a specificity of 93%. The SUVmax/SUVliver ratio had at a
cut-off value of 1.5, the highest accuracy with a sensitivity of
82% and a specificity of 93%.
DISCUSSION
In this prospective study we have analysed the value of the
integrated FDG-PET/CT scan for assessing intrathoracic lymph
nodes in patients with NSCLC. Its accuracy for predicting
malignant lymph node invasion was found to be higher than
with a CT scan. We also found that the SUVmax/SUVliver ratio, a
quantitative measure of FDG uptake, predicts malignant
invasion in the intrathoracic lymph node with an accuracy
comparable to that obtained with the integrated FDG-PET/CT
fusion images. However, neither the interpretation of the
integrated FDG-PET/CT fusion images nor the calculated cut-
offs enabled us to discontinue using tissue-based lymph node
staging in NSCLC because all the test characteristics were below
the threshold of 95% at which malignant lymph node invasion
can be confidently ruled in or out. Therefore, neither a positive
nor a negative integrated FDG-PET/CT scan allows the clinician
to confidently predict whether or not an intrathoracic lymph
node is malignant.
The advantage of the integrated FDG-PET/CT scan over the CT
scan as well as the FDG-PET scan in thoracic oncology is the fact
that the spatial resolution of the integrated scan is much higher
than with the FDG-PET scan. Because of co-acquisition and
fusion, FDG uptake can be exactly localised even in relatively
small focal abnormalities such as intrathoracic lymph nodes. This
allows a detailed analysis of the value of SUV-based variables
within a certain area of interest defined by the anatomical borders.
We chose SUVmax, SUVmean and a tumour-to-background ratio
SUVmax/SUVliver and applied these parameters not only to primary
tumours but also to intrathoracic lymph nodes.
It has been shown in several retrospective series that the
SUVmax obtained with FDG-PET scanning of the primary
tumour predicts both stage and survival of the patient with
NSCLC.10 11 A correlation between T stage and SUVmax was
found by Cerfolio et al11 for T1 and T2 tumours but not for T3
and T4 tumours. The same authors also suggested that
squamous cell carcinomas have a higher SUVmax than other
pathological subtypes.11 SUVmax was proposed as a variable
because it was suggested that its reproducibility is better than
for SUVmean.
16 However, others have suggested that SUVmean as
well as the SUVmax/SUVliver ratio give more stable and reliable
results.15
In our prospective series we analysed these SUV-based
characteristics of the primary tumour with integrated
Figure 1 Distribution of the different
standardised uptake values (SUV) according
to the pathological state of the intrathoracic
lymph node (LN).
Figure 2 Receiver operating characteristic (ROC) curves for intrathoracic
lymph node staging with PET/CT variables. SUV, standardised uptake value.
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FDG-PET/CT scanning and found that the clustering of
SUVmean and the SUVmax/SUVliver ratio was better than that
of SUVmax. This suggests that the former two might be more
reliable and stable than SUVmax. Although our data also
confirm that T1 tumours had a lower SUVmax than T2–4
tumours,11 we did not observe a difference between the
different pathological subtypes.
For lymph node staging, we found that the integrated FDG-
PET/CT scan performed better than the CT scan in terms of
specificity (85% vs 61%, p = 0.002) but not sensitivity (84% for
both). It is already known that FDG-PET scans are better than
CT scans for staging of intrathoracic lymph nodes.6–8 17
However, Shim et al18 directly compared the accuracy of CT
and integrated FDG-PET/CT scanning and suggested that the
integrated FDG-PET/CT scan is superior for lymph node staging.
Our data confirm this finding and further suggest that a visual
interpretation of the fusion images is not sufficiently accurate
to avoid invasive tissue specimen-based lymph node staging.
Because the implication of a false positive staging evaluation is
a missed opportunity for surgical care, we confirm that, as for
FDG-PET, a positive integrated FDG-PET/CT result does not
confidently rule in lymph node invasion. de Langen et al19 found
that lymph nodes measuring 10–15 mm without FDG uptake
had a post-test probability for malignant invasion of only 5%, so
they suggested that these patients do not need further
mediastinal investigation. Since the absolute number of false
negative lymph nodes in our series was low, we are cautious
about drawing firm conclusions on the negative predictive
value of integrated FDG-PET/CT scans. Nevertheless, we
calculated a specificity of 85% and a negative predictive value
of 90%, which compares with the findings of Shim et al.18
We also determined whether the accuracy of intrathoracic
lymph node staging could be improved by calculating SUV
variables on the fusion images. As expected, we found that
enlarged malignant lymph nodes have significantly higher SUV
values than benign ones. With an FDG-PET scan it was
proposed that a SUVmax cut-off of 4.4 was the best threshold to
discriminate between benign and malignant lymph nodes.17
With the integrated FDG-PET/CT scan, we calculated ROCs for
SUVmax and also for SUVmean and the SUVmax/SUVliver ratio for
lymph node staging and found that optimal cut-off points for
all three variables could be identified. For SUVmax we found
that the optimal threshold for discriminating malignancy was
2.9. The discrepancy between published data17 and our findings
could be partly attributed to the fact that FDG-PET techniques
have evolved over the past 10 years resulting in more sensitive
cameras, and also to the fact that different technology was used
for the attenuation correction and for the calculation of the
SUV data. For an FDG-PET examination, an external cesium
source is used for calculating the attenuation correction while,
for an FDG-PET/CT camera, the CT data are used to calculate
the attenuation correction. This is the reason why we also
included a ratio as variable (SUVmax/SUVliver) so that camera-
specific variables could be omitted. In addition, the lower
SUVmax threshold in our study could also be related to the fact
that we were able to delineate exactly the nodal focus on the
integrated FDG-PET/CT fusion images.
More importantly, our results indicate that a thoracic
oncology clinic working with FDG-PET or with integrated
FDG-PET/CT should not automatically rely on published SUV-
based cut-off values but should determine their own machine-
specific cut-off points. Although at a cut-off point of 1.5 the
accuracy of the SUVmax/SUVliver ratio was comparable to the
one obtained with the fusion images, calculated SUV values
also do not replace lymph node tissue diagnosis.
This study has a number of limitations. A number of methods
encompassing echo-endoscopy and surgical staging procedures
were used to obtain lymph node pathology. Although all
negative echo-endoscopies were confirmed with surgery, it is
clear that patients who had proven N2/N3 disease after echo-
endoscopy did not have full pathological mapping of the
mediastinum. In addition, although over 100 lymph nodes were
characterised, it is inevitable that—for the assessment of test
variables—false negative and false positive findings are
calculated on relatively small numbers. As discussed above,
this means that the interpretation of negative predictive values
of a small lymph node which is FDG-PET/CT negative should be
done with caution. Furthermore, the data were not corrected
for possible intrasubject correlation between nodes. Although
re-calculation of the test characteristics at the patient level did
not show a difference from the data obtained at the single
lymph node level, this must be taken into account when
interpreting the data.
In conclusion, integrated FDG-PET/CT scanning has an
overall accuracy which is too low to replace invasive intrathor-
acic lymph node staging in patients with NSCLC. The visual
interpretation of the fusion images of the integrated FDG-PET/
CT scan can be replaced by the quantitative variable SUVmax/
SUVliver without loss of accuracy for staging of intrathoracic
lymph nodes.
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I
n this observational prospective multicentre study that enrolled 2481 patients, the authors
tried to highlight the relationship between chronic obstructive pulmonary disease (COPD) and
a number of outcomes following an acute myocardial infarction (MI).
One-year mortality and rehospitalisation rates were significantly higher in patients with COPD
than without (15.8% vs 5.7%) and (48.7% vs 38.6%), respectively. In addition, patients with
COPD had worse health status at baseline as well as at 1 year and a trend toward a higher
prevalence of angina at 1 year. Not surprisingly, patients with COPD had fewer coronary
revascularisation procedures and less use of b blockers, aspirin and cardiac rehabilitation.
With the well-documented role of b blockers in improving survival post-MI even in patients
with COPD, it is possible that more frequent usage of these agents, particularly the cardio-
selective agents, in the study population could have led to a better 1 year survival than observed
and possibly a lower prevalence of angina, again at 1 year.
The study used clinical rather than pulmonary function test definition of COPD and as a
consequence could have misclassified some patients with possible inclusion of non-COPD
patients, for example those with asthma. Furthermore, the outcomes could have been influenced
by the severity of COPD, which the authors were unable to classify. Nevertheless, the data
suggest that patients with acute MI and COPD have a substantially worse prognosis in terms of
mortality and health status. This cohort of patients therefore warrants careful attention and
closer follow-up.
Nabil M Al Lawati
Clinical Fellow, University of British Columbia, Canada; drnabilm@yahoo.com
Integrated FDG-PET/CT in lung cancer staging 701
www.thoraxjnl.com
 on 8 August 2007 thorax.bmj.comDownloaded from 
